Newly engineered monoclonal antibody moves toward clinical testing

January 29, 2014

(Medical Xpress)—Using monoclonal antibodies to fight cancer is a complex, yet promising area of study. At Memorial Sloan Kettering Cancer Center, physician-scientists have focused their attention on expanding the current therapeutic antibody repertoire, and believe a newly developed platform will do just that – ultimately leading to new and innovative treatments for cancer patients with a broad range of malignancies.

Unlike other human therapeutic monoclonal antibodies that can only target proteins found on the outside of , the new antibody series, called ESK, is capable of recognizing the presence of WT1, a protein that is nestled within a cell and is overexpressed in a range of leukemias and other cancers. WT1 is a critically important target for anticancer drugs because it is a widely expressed oncogenic protein, meaning that it supports the formation of cancer. WT1 is rarely found in healthy , so toxic side effects are also less likely.

Memorial Sloan Kettering and Eureka Therapeutics recently entered into a licensing agreement with Novartis to develop this unique monoclonal antibody. Under the terms of the agreement, Memorial Sloan Kettering and Eureka Therapeutics grant Novartis an exclusive, world-wide license to develop ESK antibodies for all indications. In return, Memorial Sloan Kettering and Eureka Therapeutics receive an up-front payment and potential future payments upon achievement of development, regulatory, and sales milestones, and annual net sales royalty payments. Novartis will fund and execute the development and commercialization of the drug.

"There has not been a way to make small molecule drugs that can inhibit WT1 function before now," said David A. Scheinberg, MD, PhD, Chair of the Sloan Kettering Institute's Molecular Pharmacology and Chemistry Program, and an inventor of the antibody. "Our ongoing research shows that we can use a monoclonal antibody – which works alone to activate the immune system – to recognize a cancer-associated protein from inside a cell and to kill that cell. There are many other similar cancer-related intracellular proteins that are now new potential targets."

Discovered during a joint research effort led by Dr. Scheinberg, his colleagues at Memorial Sloan Kettering, and Dr. Cheng Liu from Eureka Therapeutics, Inc., ESK was engineered to mimic the binding properties of a T cell receptor, a key component of the body's immune system. T cells have a receptor system that is designed to recognize proteins inside cancer cells. As these internal proteins break down as part of the regular cellular process, receptors known as HLA molecules carry fragments of those proteins – called peptides – to the surface of the cell. When T cells recognize certain peptides as abnormal, the T cell kills the diseased cell.

Research published in March 2013 by Dr. Scheinberg's lab, in collaboration with Eureka Therapeutics, showed that ESK antibodies were able to recognize the WT1 peptide even though the antibody itself did not enter the cells. ESK killed cancer cells in mouse models for several different types of human leukemias and cancers. At the 2013 American Society of Hematology annual meeting, the teams also reported on the development of new versions of the ESK antibody that directly activated human T cells or more effectively. In animal models, the ESK antibodies were more effective than several traditional tyrosine kinase inhibitors (TKI) against highly TKI-resistant leukemias.

"We are excited to enter into this licensing agreement with Novartis that will help to bring this new agent into clinical testing, and our work will continue in developing methods to optimize the use of to treat cancer, until its full potential has been met," said Dr. Scheinberg.

Explore further: New monoclonal antibody developed that can target proteins inside cancer cells

Related Stories

New monoclonal antibody developed that can target proteins inside cancer cells

March 13, 2013
Researchers have discovered a unique monoclonal antibody that can effectively reach inside a cancer cell, a key goal for these important anticancer agents, since most proteins that cause cancer or are associated with cancer ...

Macrophages target tumor cells following monoclonal antibody therapy

January 16, 2014
Monoclonal antibodies directed against tumor antigens have proven effective for treating some forms of cancer. Despite the increasing use of monoclonal antibody therapy, it is not clear how these antibodies drive tumor removal.

New artificial protein mimics a part of the HIV outer coat

October 22, 2013
A team of scientists at Duke Medicine and Memorial Sloan-Kettering Cancer Center has created an artificial protein coupled with a sugar molecule that mimics a key site on the outer coat of HIV where antibodies can bind to ...

Cancer Research UK launches trial of new lymphoma treatment

January 29, 2014
Cancer Research UK's Drug Development Office (DDO) has launched a new clinical trial to treat lymphoma patients using the body's own immune system to attack cancerous B-cells growing out of control.

Monoclonal antibody targets, kills leukemia cells

March 25, 2013
Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells.

Common blood cancer may be initiated by single mutation in bone cells

January 22, 2014
Acute myeloid leukemia (AML) is a blood cancer, but for many patients the cancer may originate from an unusual source: a mutation in their bone cells.

Recommended for you

Clear link between heavy vitamin B intake and lung cancer

August 22, 2017
New research suggests long-term, high-dose supplementation with vitamins B6 and B12—long touted by the vitamin industry for increasing energy and improving metabolism—is associated with a two- to four-fold increased lung ...

Study identifies miR122 target sites in liver cancer and links a gene to patient survival

August 22, 2017
A new study of a molecule that regulates liver-cell metabolism and suppresses liver-cancer development shows that the molecule interacts with thousands of genes in liver cells, and that when levels of the molecule go down, ...

Study provides insight into link between two rare tumor syndromes

August 22, 2017
UCLA researchers have discovered that timing is everything when it comes to preventing a specific gene mutation in mice from developing rare and fast-growing cancerous tumors, which also affects young children. This mutation ...

Retaining one normal BRCA gene in breast, ovarian cancers influences patient survival

August 22, 2017
Determining which cancer patients are likely to be resistant to initial treatment is a major research effort of oncologists and laboratory scientists. Now, ascertaining who might fall into that category may become a little ...

Zebrafish larvae could be used as 'avatars' to optimize personalized treatment of cancer

August 21, 2017
Portuguese scientists have for the first time shown that the larvae of a tiny fish could one day become the preferred model for predicting, in advance, the response of human malignant tumors to the various therapeutic drugs ...

Scientists discover vitamin C regulates stem cell function, curbs leukemia development

August 21, 2017
Not much is known about stem cell metabolism, but a new study from the Children's Medical Center Research Institute at UT Southwestern (CRI) has found that stem cells take up unusually high levels of vitamin C, which then ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.